$35,500,000

Acquisition by Ligand
$35,500,000

Series B Preferred Stock
 

Spinout from Mount Sinai Health System
$2,100,000,000

Partnership with AstraZeneca
$250,000,000

Fairness Opinion


Merger with Daré
$320,000,000

Acquisition of Zoladex


Merger with Capnia
$476,000,000

Acquisition of Performance Optics
$70,000,000

N. & S. America and India Partnership with Metuchen
$150,000,000

Preferred Stock


Acquisition by Midatech Pharma PLC


Acquisition by Becton Dickinson
$75,000,000+

Acquisition by Boston Scientific
$20,000,000

Strategic Investment by Hanmi Pharmaceutical


Acquisition of SPRIX® from Luitpold
$335,000,000

Partnership with CureTech
$120,000,000

Acquisition by Nicox S.A.
$337,500,000

Acquisition of SPL
$43,400,000

Series B Preferred Stock & Debt
$40,000,000

Acquisition by Becton Dickinson
$61,000,000

Africa, Middle East, & CIS Partnership with Sanofi
$300,000,000

North American Partnership with Auxilium
$250,000,000+

Acquisition by Actelion
$100,000,000

European Partnership with Menarini
$700,000,000

Acquisition by Pfizer


Acquisition by Bionomics
$50,000,000

Strategic Investment by Baxter
$812,500,000

European Partnership with Baxter


Acquisition by Sanofl
$22,500,000

Series B Preferred Stock
$45,000,000

Series C Preferred


Acquisition of ROXRO


Acquisition by OriGene


Fairness Opinion for Acquisition of diaDexus


Acquisition by Clarient


Acquisition of PharmaForce
$765,000,000

Global Partnership with Astellas for XTANDI
$50,000,000

Series B Preferred Stock
$184,000,000

Acquisition by Roche


Acquisition by Tethys Bioscience


Acquisition by Thermo Fisher Scientific
$26,500,000

Series C Preferred Stock


Acquisition of Genomics Division by Ocimum
$16,000,000

Series D Preferred Stock
$41,200,000

Series C Preferred Stock


Acquisition by LabCorp
$44,000,000

Series E Preferred Stock
$31,000,000

Series C Preferred Stock
$53,000,000

Series B Preferred & Debt


Acquisition by Genetix
$85,000,000

Series B Preferred & Debt
$60,000,000

Series C Preferred Stock


Acquisition by Nektar


Acquisition by Invitrogen


Acquisition by Fisher Scientific
$62,500,000

Series D Preferred Stock


Acquisition by Agilent Technologies
$65,000,000

Series C Preferred Stock

Our team has advised on over:
> 160 life science transactions*     > 14 billion in M&A transactions*     > 8 billion in financings*
* Transactions completed by principals, including those completed at other firms

Mergers & AcquisitionsPrivate FinancingsPublic Financings
AcquirerTargetAmount
Enzon PharmaceuticalsAbelcet product from Elan$360,000,000
Smith & Nephew plc Acufex unit of American Home Products$141,000,000
Smith & Nephew plc Advanced Tissue Sciences (Joint Venture Formation) $70,000,000
NektarAerogen$32,000,000
MDLAfferent SystemsUndisclosed
AstellasAgensys$537,000,000
Ligand ALRT formed with AllerganUndisclosed
Marquette ElectronicsAmerican Home Products (Divestiture of Corometrics) $74,000,000
Gensia Aramed$38,000,000
Bio ParticipationsBecton, Dickinson and Company (Sale of Equity Stake of BMH S.A.)Undisclosed
Marmon Group BG SulzleUndisclosed
GenzymeBiosurface TechnologyUndisclosed
MedchemC.R. Bard$102,000,000
ArQuleCamitro$85,000,000
CephalonCephalon Clinical Partners Undisclosed
Ciba-Geigy Ltd.Chiron Corporation$2,000,000,000
Purdue FrederickCoCensys$9,500,000
Chiroscience Darwin Molecular $120,000,000
Johnson & Johnson DePuy$3,700,000,000
InvitrogenDexter and Life Technologies$1,900,000,000
Alkermes Enzytech$33,000,000
Protein Design LabsESP Pharma$500,000,000
Structural BioinformaticsGeneFormaticsUndisclosed
Bio-Technology General Gynex$52,185,000
Eli LillyIsis Pharmaceuticals$200,000,000
Pacific Dunlop Ltd.Johnson & Johnson Glove Business $98,000,000
ArrisKhepri$22,000,000
PfizerMedivation $725,000,000+
Novartis Nektar$115,000,000
PerkinElmer, Inc. NEN Life Sciences $405,000,000
Autocyte Inc. NeoPath$96,000,000
GenzymeNeozyme II $109,000,000
Cell Therapeutics Novuspharma S.p.A.$238,000,000
Arca BiopharmaNuvelo Undisclosed
St. Jude Medical, Inc. Pacesetter Business of Siemens AG $500,000,000
Amersham International plc Pharmacia Biotech (Joint Venture Formation) Undisclosed
Incyte Proteome$77,000,000
Corixa Ribi Immunochem$58,500,000
Investor Group Roche (Sale of Cedia Diagnostics Business) Undisclosed
CephalonSalmedix$160,000,000
Pacific Dunlop (Ansell Int'l Unit) Smith & Nephew plc (Perry Glove Division)$55,000,000
Sulzer Medica Spine-Tech $595,000,000
IncyteSynteni $114,000,000
St. Jude Medical, Inc.Telectronics, Inc.$135,000,000
CentocorTocor II $90,000,000
Myriad Genetics (spin-off of pharma business) UndisclosedUndisclosed
St. Jude Medical, Inc. Ventritex, Inc.$363,000,000
UCB S.A. (Belgium) Whitby Pharmaceutical Subsidiary of Ethyl Corp. (Divestiture of Subsidiary) $63,000,000
Agensys$42,800,000    AGY Therapeutics$31,300,000    Alkermes$46,000,000
Amylin Pharmaceuticals$100,000,000    Ariad Pharmaceuticals$46,000,000    AtheroGenics, Inc.$20,600,000
Caliper Technologies$110,400,000    Censtor$20,900,000    Centene$18,000,000
Cephalon $125,000,000    Cephalon$45,000,000    Corgentech $50,400,000
DAOU Systems$12,000,000    Darwin $30,000,000    Durect$20,000,000
DUSA Pharmaceuticals$42,750,000    Gene Logic$20,000,000    Genentech$72,500,000
Genesoft $21,800,000    Gensia$26,300,000    Gensia $80,000,000
Genzyme$36,800,000    Halozyme Therapeutics $17,000,000    Halozyme Therapeutics$14,000,000
HealthCentral$22,000,000    IGEN$25,000,000    Insite Vision$8,800,000
Intermune$27,300,000    Invitrogen$172,500,000    Khepri Pharmaceuticals$11,000,000
LogistiCare$20,000,000    Martek Biosciences$20,300,000    Martek Biosciences$10,000,000
Maxim$20,600,000    Myogen, Inc.$66,400,000    Neocrin$16,000,000
NetGenics $17,700,000    Paradigm Genetics$28,000,000    Protein Design Labs, Inc. $150,000,000
ReGen Biologics$8,600,000    Repligen$45,000,000    Ribi ImmunoChem$12,000,000
Saegis Pharmaceuticals$30,000,000    Sciquest.com$37,500,000    Selfcare$41,500,000
Signal Pharmaceuticals$12,000,000    Skila Inc.$26,100,000    Solexa$65,000,000
Solexa$32,000,000    Sunesis Pharmaceuticals$45,000,000    Synergen$52,500,000
Targeted Genetics, Inc. $17,500,000    Targeted Genetics, Inc.$30,300,000    The Liposome Company, Inc. $15,000,000
Therion $10,500,000    Transgenomic $12,000,000    Transkaryotic Therapies $15,600,000
Valentis, Inc.$19,200,000    Xenon Genetics$44,900,000   
Array BioPharma$91,000,000Follow-On    Atherogenics$48,000,000Initial Public Offering
AutoImmune$56,000,000Follow-On    Axys$17,500,000Initial Public Offering
Axys$44,900,000Follow-On    Caliper Technologies $83,000,000Initial Public Offering
Centocor$64,700,000Follow-On    Centocor$132,800,000 Follow-On
Cephalon$89,700,000Follow-On    CoCensys$15,800,000Follow-On
Connetics$22,800,000Follow-On    Discovery Partners $103,500,000Initial Public Offering
Dura$160,300,000Follow-On    Dura$158,700,000Follow-On
Durect $96,600,000Initial Public Offering    Endovascular Tech.$24,000,000Initial Public Offering
Exelixis Pharmaceuticals$118,000,000 Initial Public Offering    Genencor International $145,000,000 Initial Public Offering
Genomic Health$47,000,000Follow-On    Gensia $68,000,000 Follow-On
Gensia/Aramed $50,000,000Initial Public Offering    Gilead$82,000,000Follow-On
I-Stat$35,200,000Follow-On    IGEN $30,000,000Initial Public Offering
ImmuLogic$25,800,000Follow-On    Incyte$34,900,000Follow-On
Incyte $92,300,000Follow-On    Intermune$125,000,000Initial Public Offering
Invitrogen$147,500,000Follow-On    King$91,900,000 Initial Public Offering
Lexicon Genetics $220,000,000Initial Public Offering    Ligand$38,000,000 Follow-On
MannKind Corporation$515,000,000Follow-On/Convertible Offering    Medicis $197,000,000Follow-On
Myriad Genetics$197,000,000Follow-On    NeoPath $60,000,000Follow-On
Novoste$55,200,000Follow-On    Orexigen Therapeutics$97,000,000Initial Public Offering
OrthoLogic $78,400,000Follow-On    Protein Design Labs, Inc. $362,000,000Follow-On
SangStat$42,000,000 Follow-On    SangStat $78,000,000 Follow-On
Seattle Genetics$100,000,000Follow-On    Shire$100,000,000 Follow-On
Sonus $20,000,000 Initial Public Offering    SpectRx$15,400,000Initial Public Offering
Sugen $24,800,000Follow-On    Sulzer Medica $620,000,000Initial Public Offering
Sunesis Pharmaceuticals$42,000,000Initial Public Offering    Telik $35,000,000Initial Public Offering
Uromed$40,000,000 Initial Public Offering    Variagenics$88,000,000 Initial Public Offering
Versicor $50,600,000Initial Public Offering